Zoladex
HR+/HER2-negative Breast Cancer
Totus MedicinesPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the HR+/HER2-negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Totus Medicines | Phase 2 | B |
Palbociclib Totus Medicines | Phase 2 | B |
POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X) SynDevRx, Inc. | Phase 1/2 | CCC |
Letrozole Totus Medicines | Phase 1 | CC |
Ribociclib Totus Medicines | Phase 1 | CC |
LEUPROLIDE Totus Medicines | Phase 1 | CC |
Tos-358 Totus Medicines | Phase 1 | CC |
Same molecule, other indications
Zoladex is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →